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Recent advances in the technology of radiotherapy have enabled the development of new
therapeutic modalities that deliver radiation with very high accuracy, reduced margins and
high dose conformation, allowing the reduction of healthy tissue irradiated and therefore
minimizing the risk of toxicity. The next step was to increase the total tumor dose using
conventional fractionation (which remains the best way to relatively radioprotect healthy
tissues when large volumes are treated) or to use new fractionation schemes with greater
biological effectiveness. Based on the experience gained in radiosurgery, the latter way was
chosen for small and well-defined tumors in the body. Stereotactic body radiotherapy deliv-
ers  high doses of radiation to small and well-defined targets in an extreme hypofractionated
(and accelerated) scheme with a very high biological effectiveness obtaining very good ini-
tial  clinical results in terms of local tumor control and acceptable rate of late complications.
In  fact, we realize a posteriori that it was not feasible to administer such biologically equiv-
alent  dose in a conventional fractionation because the treatment could last several months.
So  far, these new therapeutic modalities have been developed due to technologic advances
in  image guidance and treatment delivery but without a solid biological basis. It is the role
of  traditional radiobiology (and molecular radiobiology) to explain the effects of high doses
of  ionizing radiation on tumor and normal tissues. Only through a better understanding of
how high doses of ionizing radiation act, clinicians will know exactly what we  do, allowing
us  in the future to refine our treatments. This article attempts to describe through simpleand  understandable concepts the known aspects of the biological action of high doses of
radiation on tumor and normal tissues, but it is clear that we need much more basic research
to  better understand the biology of high doses of radiation.
© 2017 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
single dose or a few fractions with a high degree of precision1.  BackgroundStereotactic body radiation therapy is a new radiation treat-
ment method to deliver, with high accuracy, a high dose of
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1507-1367/© 2017 Greater Poland Cancer Centre. Published by Elsevier radiation to small and well-defined targets, utilizing either awithin the body.1 This new high technology modality requires
a high degree of precision, accuracy and reproducibility of
the entire treatment delivery process. Maneuvers to limit the
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ovement  of the target volume and stereotactic localization
f the lesion or image  guidance are mandatory for target local-
zation, minimization of margins and dose delivery. Patient
mmobilization systems should be very accurate and radiation
quipment should have mechanical tolerances for radiation
elivery of ±2 mm.  In order to minimize normal tissue tox-
city, conformation of high doses to the target and rapid dose
all-off gradients away from the target is performed using mul-
iple coplanar, non-coplanar static fields or arc therapy. It must
e emphasized that quality assurance is a critical step of the
ntire process.2
Initial clinical experiences with SBRT show impressive
esults in terms of local tumor control and acceptable late
omplications rate. This high rate of local tumor control, not
ully explained by our current understanding of the response
f tumors to high doses of radiation, raises the question of
hether there is some new biology to explain these results.3
lthough, from a biological point of view, the major fea-
ure that differentiates SBRT from conventional radiation
reatment is the delivery of large doses in one or a few frac-
ions which results in a high biological effective dose, the
adiobiology of SBRT is poorly understood. Other important
adiobiological distinctive features of SBRT are small irradi-
ted volumes, inhomogeneous dose distribution and short
verall treatment time. The classic basic principles of frac-
ionation, namely the Withers four R’s of radiotherapy (repair,
epopulation, redistribution and reoxygenation)4 and intrin-
ic radiosensitivity cannot be totally ignored in explaining
he effects of high doses of ionizing radiation on tumors and
ormal tissues but new radiobiological knowledge on the bio-
ogical effects of high doses of ionizing radiation is emerging
llowing us in the future to better understand how high doses
f ionizing radiation act and refine SBRT treatments.
.  Classic  biological  basis  of  high-dose
adiotherapy  on  tumors
.1.  Tumor  radiosensitivity
adiosensitivity is the susceptibility of cells (tissues and
rgans) to be damaged and inactivated by ionizing radiation.
o compare the radiosensitivity of different types of cells, we
an use parameters directly read on the cell survival curve
s the surviving fraction at 2 Gy (SF2) or parameters derived
rom mathematical models. The linear-quadratic (LQ) formal-
sm is the most commonly used tool to compare fractionation
ensitivity, to model the effect of fractionation in convention-
lly fractionated radiotherapy and to predict tumor response
o altered fractionation regimens. The model is based on the
ssumption that cell death is due to DNA strand breaks. How-
ver, studies have shown that the LQ model overestimates
ell killing at high single doses because it predicts a survival
urve that continuously bends downward whereas the exper-
mental data are consistent with a constant slope at high
oses.5,6 Therefore, there is concern that LQ model does not
ccurately predict tumor cell response at the higher doses per
raction used in SBRT. In fact, there is a controversy about the
imitations of the LQ model for predicting the biological effec-
iveness of SBRT. Proponents of the use of the model argue
hat it is a mechanistic, biologically based model related toiotherapy 2 2 ( 2 0 1 7 ) 86–95 87
single and double-strand DNA breaks; it has sufficiently few
parameters to be practical; it has well-documented predictive
properties for fractionation/dose-rate effects in the labora-
tory and it is reasonably well validated, experimentally and
theoretically, up to about 10 Gy/fraction and would be reason-
able for use up to about 18 Gy per fraction.7 However, other
authors believe that the use of the LQ model is inappropri-
ate because much of the data used to generate the model are
obtained in vitro at doses well below those used in SBRT and
does not consider the impact of radiation on cells other than
the tumor cells (for example, the indirect tumor cell death
caused by vascular damage); it does not accurately explain
the observed clinical data and ignore the impact of radioresis-
tant subpopulations of cells.8 In any case, literature of SBRT
is full of examples where BED (biologically effective dose) or
EQD2 (equivalent dose in 2 Gy fractions) are used to compare
different fractionations.8–11,24 The only parameter required to
perform the calculations is the ˛/  ̌ ratio. Although there are
many uncertainties, the ˛/  ̌ ratio normally used for early-
responding tissues and most tumors is ≥10 Gy. No need to say
that the choice of this parameter is critical to the correct cal-
culations of BED or EQD2. For instance, some slow-growing
tumors such as prostate cancer, breast cancer, melanoma and
soft tissue sarcomas have ˛/  ̌ ratios well below 10 Gy. Two
examples of how to perform the calculations are shown below.
1. Assuming full reoxygenation and complete repair of sub-
lethal damage between fractions and no repopulation,
calculate the BED and EQD2 of a treatment that delivers
54.00 Gy in 3 fractions of 18.00 Gy to a lung tumor (estimated
˛/  ̌ ratio = 10.00 Gy).
BED(˛/ˇ) = D · (1 + d/˛/ˇ)
BED10 = 54 · (1 + 18/10) = 151.20 Gy10
EQD2 = BED(˛/ˇ) = D · (1 + 2/˛/ˇ)
EQD2 = 151.20 = D · (1 + 2/10) = 126 Gy
Therefore, using the simplest formula of LQ model, 54.00 Gy
delivered in 3 fractions to a lung tumor is equivalent to
126 Gy delivered in 63 fractions of 2 Gy for an estimated ˛/ˇ
ratio of 10.00 Gy.
2. Assuming full reoxygenation and complete repair of sub-
lethal damage between fractions and no repopulation,
calculate the BED and EQD2 of a treatment that delivers
36.25 Gy in 5 fractions of 7.25 Gy to a prostate cancer (esti-
mated ˛/  ̌ ratio = 1.5 Gy).
BED(˛/ˇ) = D · (1 + d/˛/ˇ)
BED1.5 = 36.25 · (1 + 7.25/1.5) = 211.46 Gy1.5
EQD2 = BED(˛/ˇ) = D · (1 + 2/˛/ˇ)
EQD2 = 211.46 = D · (1 + 2/1.5) = 90.62 Gy
Therefore, using the simplest formula of LQ model, 36.25 Gy
delivered in 5 fractions to a prostate cancer is equivalent to
90.62 Gy delivered in 45 fractions of 2 Gy for an estimated
˛/  ̌ ratio of 1.50 Gy.
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Table 1 – Tumor control probability as a function of isocenter BED8.6, EQD2, BEDUSC, and SED (values read directly on the
curves 1 and 2 in Mehta publication).12
TCP (%) BED (Gy8.6) EQD2 (Gy) BEDUSC (GyUSC) SED (Gy)
50 61 50 47 35
60 75 65 60 50





For early-stage non-small cell lung cancer (NSCLC), clini-
cal data suggest that radiobiological modeling using the LQ
formula is adequate to explain the efficacy of SBRT. Recently,
Mehta et al. reviewed the available clinical tumor control (≥2
years) probability (TCP) data for SBRT (single dose and 3–8
multifractions) and 3-dimensional conformal radiation ther-
apy (3D-CRT) to determine the relationship between TCP and
BED in medically inoperable stage I NSCLC.12 They found a
sigmoidal relationship between TCP as a function of BED with
TCP ≥ 90% achieved with BED ≥ 159 Gy8.6 and EQD2 ≥ 125 Gy
(Table 1) (Figures 1 and 2 in Mehta publication). Replotted
data distinguishing between single fraction SBRT, multifrac-
tion SBRT and 3D-CRT showed a monotonic relationship
between TCP and BED for SBRT and 3D-CRT data (Figure 1
in Brown editorial) suggesting that SBRT and 3D-CRT pro-
duce the same TCP probability when adjusted for BED.13 The
authors concluded that at least for early NSCLC, the high
rate of local tumor control achieved by SBRT can be fully
explained by the much higher biological effective dose and
that there is no need to invoke a “new biology” to explain these
results.13,14
A new radiobiological model called universal survival curve
(USC) to compare different fractionations of both conven-
tionally fractionated radiotherapy and SBRT was published
in 2008.15 This model was constructed to provide a supe-
rior approximation of the experimentally measured survival
curve data in the high-dose range by hybridizing the LQ model
survival curve for the low-dose range (the shoulder) and the
multitarget model asymptote for high-dose range. According
to the USC model, DT is the transition dose from LQ model
to the multitarget model. From this hybrid model, two equiv-
alent functions can be derived: the biologically effective dose
and the single fraction equivalent dose (SFED) for both conven-
tionally fractionated radiotherapy and SBRT. BED is calculated
by the LQ formula if dose per fraction is below the transition
dose DT and by USC formula if dose per fraction is higher than
DT. SFED is defined as the dose delivered in one fraction that
has the same biological effect as the tested dose-fractionation
scheme. Again, two  different USC formulas should be used
depending on whether the dose per fraction is lower or higher
than DT. Equating the two formulas allows to calculate the
Standard Effective Dose (SED) that is the total dose adminis-
tered in 2 Gy fractions for the same effect.
The validity of this new model was tested using previously
published radiosensitivity parameters of human lung cancer
cell lines. The model fits very well with a cell survival curve of
15H460 NSCLC obtained by clonogenic assay. The main weak-
ness of the model is its dependence on five radiobiological
parameters: ˛, ˇ, D0, Dq and DT. Two examples of calculations
are shown below.95 87
124 128
1. Calculation the BEDUSC, SFED and SED of a treatment
that delivers 54.00 Gy in 3 fractions of 18.00 Gy to a lung
tumor (estimated  ̨ = 0.33 Gy−1; D0 = 1.25 Gy; Dq = 1.80 Gy;
DT = 6.2 Gy and ˛/  ̌ ratio = 10.00 Gy).
BEDUSC = 1(  ̨ · D0)
·  (D − n · Dq)
BEDUSC = 1(0.33 · 1.25) · (54 − 3 · 1.80)
= 2.42 · 48.6 = 117.6 GyUSC
SFED = D − (n − 1) · Dq
SFED = 54 − (3 − 1) · 1.8 = 54 − 3.60 = 50.40 Gy
SED = 1
(˛ · D0)
· Dsbrt − nsbrt · Dq
(1 + 2/˛/ˇ)
SED = 1
(0.33 · 1.25) ·
54 − 3 · 1.80
(1 + 2/10) = 2.42 · 40.50 = 98.01 Gy
Therefore, using the formulas of USC model, 54.00 Gy deliv-
ered in 3 fractions of 18.00 Gy (>DT) to a lung tumor results
in a SFED of 50.40 Gy that is equivalent to 98.01 Gy deliv-
ered in 49 fractions of 2 Gy for an estimated  ̨ = 0.33 Gy−1;
D0 = 1.25 Gy; Dq = 1.80 Gy and ˛/  ̌ ratio = 10.00 Gy.
2. Calculation using the Universal Survival Model if 33 Gy in 3
fractions and 37 Gy in 5 fractions are equipotent fraction-
ations (estimated  ̨ = 0.33 Gy−1; D0 = 1.25 Gy; Dq = 1.80 Gy;
DT = 6.2 Gy and ˛/  ̌ ratio = 10.00 Gy).
BEDUSC = 1(  ̨ · D0)
·  (D − n · Dq)
BEDUSC = 1(0.33 · 1.25) · (33 − 3 · 1.80)
= 2.42 · 27.6 = 66.8 GyUSC
BEDUSC = 1(0.33 · 1.25) · (37 − 5 · 1.80)
= 2.42 · 28 = 67.8 GyUSC
SFED = D − (n − 1) · DqSFED = 33 − (3 − 1) · 1.8 = 33 − 3.6 = 29.40 Gy
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SED = 1
(  ̨ · D0)
· Dsbrt − nsbrt · Dq
(1 + 2/˛/ˇ)
SED = 1
(0.33 · 1.25) ·
33 − 3 · 1.80
(1 + 2/10) = 2.42 · 23 = 55.66 Gy
SED = 1
(0.33 · 1.25) ·
37 − 5 · 1.80
(1 + 2/10) = 2.42 · 23.33 = 55.45 Gy
Therefore, using the formulas of USC model, 33 Gy in 3 frac-
tions and 37 Gy in 5 fractions are equipotent fractionations
for an estimated  ̨ = 0.33 Gy−1; D0 = 1.25 Gy; Dq = 1.80 Gy;
DT = 6.2 Gy and ˛/  ̌ ratio = 10.00 Gy.
In the study cited above for early-stage NSCLC treated with
ingle fraction SBRT, multifraction SBRT and 3D-CRT, TCP as
 function of BEDUSC calculated by USC formulas was also
igmoidal with TCP ≥ 90% achieved with BEDUSC ≥ 124 GyUSC
nd SED ≥ 128 Gy (  ̨ = 0.33 Gy−1; D0 = 1.25 Gy; Dq = 1.80 Gy;
T = 6.0 Gy and ˛/  ̌ ratio = 8.6 Gy) (Table 1) (Figures 1 and 2 in
ehta publication).12
As expected, the curves relating TCP and BED calculated by
Q model or by USC model were different but with minimal
linical significance for high dose per fraction used in SBRT.
Although the high rate of local tumor control achieved by
BRT for early NSCLC could be fully explained by the high bio-
ogical effective dose calculated by the LQ model or by the USC
odel, this may not be true for other types of tumors. Emerg-
ng evidence indicates that apart from direct tumor cell killing,
BRT can severely damage the tumor neovasculature leading
o indirect tumor cell death due to an acute decrease in blood
erfusion. If this were true, none of the two models described
bove would take into account this effect8 (see Section 4).
For liver metastases, a wide variety of SBRT dose and
ractionation schedules have been reported. Fractionation
chemes used in prospective phase I–II trials range from sin-
le fraction of 14–30 Gy 15,17 to hypofractionated schedules
f 30–75 Gy 18–22,38 delivered in 3–5 fractions in an overall
reatment time between 5–6 days and 2.5 weeks. One risk
tratified phase I trial used doses between 27.70 Gy and 60 Gy
elivered in 6 fractions over 2 weeks.23 Published reports are
ifficult to compare not only because of heterogeneity in dose-
ractionation regimens but also due to the heterogeneity in
osimetric planning and dose prescription, heterogeneity in
atient selection, primary tumor, number and volume of liver
umors, number of systemic treatments before and after SBRT
nd heterogeneity in the definition of local control. Overall,
hese phase I-II trials report local control rates ranging from
6% to 100% at 2 years. Higher doses are associated with bet-
er local control but the dose response curve for local control
s uncertain. In a pooled analysis of patients with colorectal
iver metastases treated by SBRT at 3 institutions, Chang et al.
ound in multivariate analysis that total dose, dose per frac-
ion and BED all correlated with local control. The estimated
ED10 Gy needed for a 90% local control at 1 year was 117 Gy10.
onverting this value into a 3-fraction SBRT regimen using
he LQ-formula yields an estimated total dose between 46
nd 52 Gy to achieve 90% local control.24 The same calculation
or a 5-fraction regimen results in a total dose around 55 Gy.
ased on this publication, a total prescription dose of 48 Gy or
igher in 3 fractions is recommended when possible.24 Betteriotherapy 2 2 ( 2 0 1 7 ) 86–95 89
outcome has been reported for non-colorectal liver metas-
tases. This is perhaps because most patients with colorectal
liver metastases had been heavily pretreated before SBRT.25 In
conclusion, there is not a consensus on the standard approach
to the SBRT for liver oligometastases and the appropriate
dose and fractionation scheme remains undefined. New trials
of SBRT for liver metastases are needed to clarify the dose-
fractionation local control relationship.
2.2.  Repopulation  of  tumor  cells
Repopulation of tumors cells refers to the proliferation of
the surviving clonogenic tumor cells during the course of
a fractionated radiotherapy. Once started, radiation therapy
(and chemotherapy) can trigger surviving clonogenic tumors
cells to divide faster than before, a phenomenon known as
accelerated repopulation or rapid compensatory repopulation.
It is thought that accelerated repopulation is the cause of
the detrimental effect on local control of the prolongation
of the overall treatment time and the basis for accelerated
radiotherapy in rapidly proliferating tumors. Withers was the
first to describe this phenomenon and showed that clono-
gen repopulation in squamous cell carcinomas of the head
and neck accelerates after a lag period of 4 ± 1 weeks after
initiation of radiotherapy.26 Tk (kick-off) is the elapsed time
between the start of fractionated radiotherapy and the onset
of accelerated repopulation in tumors (or rapid renewing tis-
sues). Tk has been estimated for some tumors: 3–4 weeks for
head and neck tumors,26,27 19 days for cervical cancer28 and
between 30 and 69 days, depending on the stage, for prostate
cancer.29
Although nobody really knows the onset time of accel-
erated repopulation of tumors treated with SBRT, data
derived from conventionally fractionated radiotherapy sug-
gest that this phenomenon is probably not very important for
SBRT given the relatively short overall treatment time (and
irrelevant in single dose SBRT). Therefore, reducing overall
treatment time to around one or two weeks as in fraction-
ated SBRT may be advantageous in terms of reducing the
possibility of accelerated tumor repopulation in particular
for rapidly proliferating tumors and may contribute to the
improvement of local control.30 A practical consequence is
that the mathematical repopulation term should not be added
to the simple formula if the LQ model is used to calculate
equivalences.
In spite of the above, a multi-institutional retrospective
study of 505 lung tumors treated with SBRT with a variety of
fractionation regimens surprisingly showed that shorter treat-
ment duration was significantly associated with a better local
control. Patients who received SBRT over ≤10 elapsed days
had a 2 year local recurrence of 4% versus 14% for ≥11 days
(p < 0.01).10
2.3.  Reoxygenation  of  tumors  cells
Due to the imbalance between the growth of tumor cells
and vasculature, many  rapidly proliferating tumors have
hypoxic areas because tumor cells are far from the ves-
sels and therefore are deprived of oxygen and nutrients.
In addition, newly formed vessels are abnormal, immature,
nd ra
time, volume of normal tissue or organ irradiated, type of
organ and other factors (host factors: genetic susceptibility,90  reports of practical oncology a
chaotically distributed and functionally deficient causing
areas of acute or chronic hypoxia and necrosis. It is well
known that hypoxic tumor cells are 2–3 times more radiore-
sistant than well oxygenated tumor cells and this may
be the cause of the lack of response to radiotherapy or
tumor recurrences.31 Reoxygenation, a phenomenon that
only occurs in tumor tissues, is the process by which the
surviving hypoxic tumor cells become better oxygenated
during the period after the initiation of a fractionated
irradiation and therefore more  radiosensitive to the follow-
ing radiation doses.32 The biological mechanisms involved
in the phenomenon of reoxygenation are poorly under-
stood but are probably different for acute and chronic
hypoxia. Reoxygenation can occur quickly in the case of
acute or transient decreased perfusion caused by an inter-
mittent blood flow through an abnormal and immature
vessel. On the contrary, reoxygenation of areas with chronic
hypoxia may take several hours or days to resolve, which
is believed to be due to tumor shrinkage after delayed
mitotic death and reabsorption of cellular debris. There-
fore, reducing the overall treatment time reduces a chance
that reoxygenation of chronic hypoxic tumor areas may
occur. Although tumor shrinkage is probably faster when
using SBRT because many  tumor cells are killed and die
more  rapidly due to other modes of radiation-induced cell
death different from delayed mitotic death and some extent
of reoxygenation may occur, the short overall treatment
time plays against the reoxygenation of hypoxic tumor
areas, particularly in larger tumors presumably less oxy-
genated. Using this theoretical reasoning, some authors
advocate leaving inter-fraction intervals ≥72 h to facilitate
reoxygenation.33,45
Needless to mention that for single-fraction SBRT, reoxy-
genation is an irrelevant process and therefore the existence
of radioresistant hypoxic tumor cells constitutes a potential
problem. A recently published phase II study conducted by
RTOG comparing two  different SBRT schedules for patients
with medically inoperable stage I peripheral NSCLC showed
a primary tumor control at 1 year of 97% for a single fraction
SBRT of 34 Gy versus 92.7% for a multifraction SBRT of 48 Gy
delivered in 4 consecutive daily fractions (along with a lower
rate of toxicities).34 This and other studies with longer follow-
up (local control at 2- and 3-years of 95% and 88.1% in Indiana
University Phase II trial 35,36 and estimated 3- and 5-year pri-
mary tumor control rate of 97.6% and 93% in RTOG 0236 phase
II trial using 54 Gy in 3 fractions of 18 Gy in 1.5–2 weeks37,38)
seem to show that high doses of radiation would be able to
overcome the problem of tumor hypoxia radioresistance of
lung tumors. Although some local failures can be explained
by geographical errors, local tumor control decreases over
time especially in larger tumors. Some authors, using single
doses of SBRT, have shown differences in local tumor control
depending on tumor volume, attributing these differences to
radioresistance mechanisms associated with tumor hypoxia
and proposing to test the addition of hypoxic cell radiosensi-
tizers to a single dose of SBRT.39,45
In metastatic sites treated with multifraction SBRT, local
tumor control also seems related to the size of lesions suggest-
ing that there may be mechanisms of radioresistance perhaps
related to the existence of hypoxic areas in larger tumors.40–42diotherapy 2 2 ( 2 0 1 7 ) 86–95
2.4.  Redistribution  of  tumor  cells  in  the  cell  cycle
Radiosensitivity of cells varies depending on the cell cycle
phase in which they are at the time of irradiation, being more
radioresistant in the S-phase. Redistribution is the process
by which, after transient cell cycle arrest due to the acti-
vation of cell cycle checkpoints by radiation, the surviving
tumor cells become more  sensitive to radiation because they
progress through the cell cycle to more  radiosensitive phases.
Although the biological significance of this phenomenon, if
any, is unknown in SBRT, shortening the overall treatment
time plays against redistribution of tumor cells into more
radiosensitive phases of the cell cycle. In an in vitro study
on human promyelocitic leukemic cells, high single dose of
irradiation indiscriminately caused cell cycle arrest and inter-
phase death in all cell cycle phases.43
2.5.  Repair  of  sublethal  damage  of  tumor  cells
The existence of molecular mechanisms of DNA damage
repair allows cells to repair radiation sublethal damage before
the next radiation fraction and thus increase cell survival
(recovery) as a function of time between fractions or dur-
ing treatment delivery. Cells need time to sense and repair
radiation-induced DNA damage. Although the kinetics of
repair of sublethal damage probably involves at least two  com-
ponents, a quick and slow repair phases, it is believed that
rapidly proliferating tumors have, like early-responding nor-
mal  tissues (and unlike late-responding normal tissues), short
sublethal damage repair half-times. Therefore, there will be
no residual unrepaired damage in rapidly proliferating tumors
cells after irradiation at high doses in 24 h intervals fraction-
ation.
On the other hand, there may be some repair of sublethal
damage during irradiation if the exposure time is lengthened.
New treatment techniques and SBRT administer the dose in
a more  prolonged fraction delivery time allowing the repair
of some sublethal damage in rapidly proliferating tumor cells
during the treatment and therefore decreasing the biological
effect.44 It has been estimated that any fraction delivery that
lasts more  than half an hour can cause a clinical significant
loss of biological effect.45,46 As clinical data are lacking, it is
strongly recommended for the purpose of future studies on
biological efficacy to record and report the duration of overall
fraction time, especially if fraction delivery time is prolonged
more  than half an hour.46
3.  Classic  biological  basis  of  high-dose
radiotherapy  on  healthy  tissues  and  organs
The advantages of high doses of radiation to the tumor tis-
sues in terms of local control must be balanced against the
risk of complications mainly dependent of late-responding
tissues. Normal tissue dose tolerance depends on fraction
size, total dose, time between fractions, overall treatmentage, comorbidities and therapeutic factors: concomitant ther-
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n order to minimize the risk of toxicity, it is imperative to
inimize the volume of healthy tissue irradiated using proper
linical indications (small and well-defined targets not embed-
ed inside a functionally organized serial organ), and reducing
TV margins using modern and accurate technology, good
atient immobilization, effective maneuvers to limit target
ovements, stereotactic target localization or image  guidance
nd a good technique with conformation of high doses to the
arget and rapid fall-off doses away from the target.
.1.  Radiosensitivity  of  late-responding  tissues  and
rgans
ll the doubts expressed in Section 2.1. regarding the use of the
Q model must also be considered in its application to the pre-
iction of late effects. Due to the nature of the tissue, normal
ate-reacting tissues (with low ˛/  ̌ ratio) are more  radiosen-
itive at higher doses per fraction than rapidly proliferating
umors and early-reacting normal tissues. Therefore, and even
aking into account the normal tissue volume effect (better
olerance at lower volume), the risk of late complications is
igher at higher doses per fraction. Models of normal tissue
omplication probability (NTCP) should be used with caution
ecause they are imperfect and should be validated with more
ature data on late effects collected in the long-term moni-
oring of well conducted SBRT clinical trials.
One important question is how organs at risk are function-
lly organized. Depending on how the functional subunits are
rganized, organs can be divided into two categories. In par-
llel functioning organs (lung, liver), the different functional
ubunits are structurally well defined and perform the same
unction. They are usually large organs and as their func-
ional subunits operate separately, they show redundancy in
heir function and organ reserve (surgeons can remove part
f the organ). Serially functioning organs (spinal cord, air-
ays) have structurally undefined functional subunits that
ust work together to maintain organ function. They are
sually long organs acting as a conduit and if a part of the
rgan is seriously damaged then all the downstream function
s lost (surgeons cannot remove any part of the organ).47,48
his is the reason why the most important determinant of
erially functioning organ toxicity is the maximum dose of
adiation.35,49–52 This is also the reason why the treatment of
 tumor embedded within a serially functioning organ is not
 good indication of SBRT. On the other hand, parallel func-
ioning organs can tolerate localized high doses of radiation if
 significant volume of the organ can be avoided and so can
ontinue to maintain its function. Therefore, the most impor-
ant determinant of parallel functioning organ toxicity is the
olume of the organ irradiated and its basal functional status
comorbidities).41,51–53
.1.1.  Dose-volume  constraints  for  organs  at  risk
he report of the American Association of Physicists in
edicine Task Group 101 states that “normal tissue dose
imits for SBRT are considerably different from conventional
adiotherapy due to extreme dose-fractionation schemes and
re still quite immature”.2 Actually, most dose-volume con-
traints are based on retrospective studies or simply using
heoretical calculations based on the LQ model. Therefore,iotherapy 2 2 ( 2 0 1 7 ) 86–95 91
the dose limits should be used with care and should be con-
tinually reviewed and validated pending more  mature data
on late effects collected in the long-term monitoring of well
conducted SBRT clinical trials. For example, the initial dose
constraint for normal liver (a minimum volume of 700 mL
should receive a total dose of less than 15 Gy in 3 fractions)
used in the study of Rusthoven for liver metastases41 was
derived using BED calculations (˛/  ̌ = 3.00 Gy) from published
experiences in hepatic accelerated hyperfractionation.57 This
and other phase I trials have confirmed the validity of
this dose-volume constraint or have described new limita-
tions for single fraction or five fractions SBRT of hepatic
metastases.17,21 The phase I study of Rule established the
safety of delivering 60 Gy in 5 fractions to treat liver metas-
tases if pretreatment hepatic function was adequate and a
critical volume of 700 mL of normal liver receives a total dose
of no more  than 21 Gy in 5 fractions.21 The situation is com-
pletely different for the treatment of hepatocellular carcinoma
because associated cirrhosis causes a significant decrease in
liver tolerance to radiation.52 It should also pay special atten-
tion to centrally located hepatic lesions where the central
biliary system is a serially functioning organ.58,59
In conclusion, a prudent approach, is to use dose-
volume constraints for organs at risk summarized in
updated guidelines2,54 or determined in high-quality phase I
trials.16,21,23,35,41,52,55,56
3.2.  Repopulation  and  redistribution  of
late-responding  tissues
Although they could play a role in opposite directions (repop-
ulation increasing the proliferation of normal cells and
redistribution increasing normal cell kill) neither repopulation
nor redistribution play an important role in the normal tissue
response to high doses of ionizing radiation due to the nature
of late-reacting tissues with slow cell turnover and long cell
lifespan.
3.3.  Repair  of  sublethal  damage  of  late-responding
tissues
Incomplete repair can be a problem for some late-responding
normal tissues if large doses are administered without enough
interfraction time to allow for complete repair of sublethal
damage. It is known that the kinetics of repair of sublethal
damage of late-responding normal tissues is slower than
that of early-responding normal tissues with longer sublethal
damage repair half-times, in the order of several hours.60
Therefore if large dose fractions create more sublethal dam-
age than conventional fractions and it takes longer time to be
repaired, there will be residual unrepaired damage if inter-
fraction time is too short to allow for complete repair. If a
significant amount of residual unrepaired damage remains
after a too short interfraction time, the accumulation of
residual damage to the damage produced by the subsequent
fraction can result in an excess of toxicity. A possible exam-
ple illustrating this phenomenon is shown in the prospective
phase II clinical trial of King et al. using SBRT for low-risk
prostate cancer.61 They compared late urinary and rectal tox-
icities reported by patients using validated quality of life
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questionnaires between a SBRT schedule of 36.25 Gy in 5 frac-
tions in five consecutive days with those treated with the same
dose administered every other day. While late urinary toxic-
ity showed only a tendency toward improvement with more
protracted treatment (19% versus 5%), late moderate or severe
rectal toxicity showed a statistically significant difference also
in favor of the longer treatment (38% versus 0%; p = 0.0035).
To reduce the risk of toxicity due to the accumulation of
unrepaired residual damage and since there are no conclusive
biological or clinical data, a prudent approach is to perform
multifraction SBRT with interfraction times greater than 24 h
(remember that tumor repopulation does not seem to be a
problem if the overall treatment time is not extended too
much).
4.  Radiation-induced  vascular  damage  in
tumors
As well as the direct effect of tumor cell killing caused by dou-
ble strand breaks in DNA (and modelized in LQ formalism),
ionizing radiation can cause damage to other cellular compo-
nents of tumor microenvironment that may lead to secondary
or indirect effects.
Recently, Park et al. reviewed the studies on radiation-
induced vascular changes in human and experimental tumors
reported in the literature.62 They concluded that while the
functional vascularity in human tumors remains unchanged
or improves slightly during the early period of conventional
fractionated radiotherapy but gradually diminishes during the
later part of treatment, irradiation with doses higher than
10 Gy in a single fraction or 20–60 Gy in limited numbers of
fractions causes severe vascular damage leading to indirect
death of tumor cells due to the acute decrease in blood per-
fusion making the tumor environment hypoxic, acidic and
deprived of nutrients.
Although these observations are derived from studies
with experimental tumors, they hypothesized that similar
vascular damage would occur in human tumors irradiated
with high-dose hypofractionated radiotherapy. This theory is
supported by other experimental data. For instance, Garcia-
Barros et al. demonstrated that the exposure of transplanted
mouse fibrosarcoma and melanoma cell lines to single dose
of 15–20 Gy was followed by a rapid wave  of endothelial cell
apoptosis soon after irradiation which in turn was followed
by death of tumor cells at 2–3 days.63 Apoptosis in endothelial
cells after high doses of radiation could be induced via the acid
sphingomyelinase mediated generation of ceramide, which is
not activated with doses used in conventional fractionated
radiotherapy.64 Although this phenomenon could be highly
variable depending on fraction size, total dose of radiation,
location and tumor type, there are insufficient data to ensure
that it plays an important role in the effects of high-dose radi-
ation on all tumors.14 In fact, there is much controversy in
the literature about the existence of indirect cell death by
devascularization and, if proved true, how this indirect effect
can be modeled because it is not taken into account in the
original LQ model.3,8,13,14,64–66 A recent paper, published by
Kim reviews experimental data demonstrating the contribu-
tion of indirect cell death secondary to vascular damage todiotherapy 2 2 ( 2 0 1 7 ) 86–95
total tumor cell death.67 On the contrary, Moding et al. using
dual recombinase technology, generated primary sarcomas in
a genetically engineered mouse model with targeted genetic
mutations specifically in tumor cells or endothelial cells and
demonstrated that tumor cells, rather than endothelial cells,
are critical targets that regulate sarcoma eradication by radi-
ation therapy.68
An additional hypothesis, linked to the previous theory, to
explain the good clinical results of SBRT is the possibility that
high doses of radiation can damage the perivascular niche
where radioresistant stem cells are living.62
5.  Radiation-induced  immunologic  effects
It is not the purpose of this section to summarize the complex
world of cancer immunology and the complex interactions
between ionizing radiation and tumor microenvironment,
including immune cells, but only to introduce some concepts.
Radiotherapy has often been seen as an immunosuppress-
ive agent, but today we  know that in certain circumstances,
radiation may have immunostimulatory effects. A new form of
radiation-induced cell death, called immunogenic cell death
(ICD), has been recently described.69,70 ICD is characterized
by a massive release of cancer cell neoantigens and the
generation of molecular signals (DAMPS: damage-associated
molecular patterns) produced by dying cells acting as “eat-me”
signals promoting uptake and presentation of tumor-derived
antigens by dendritic cells. Remember that activation of
natural antitumor T cell response requires uptake and cross-
presentation of tumor-derived antigens by dendritic cells to
T cells in the draining lymph nodes. Radiation also induces
the secretion of interferon I necessary to recruit and activate
dendritic cells. This type of cell death not only induced by ion-
izing radiation can be expressed by tumor cells depending,
among others, on tumor type, genetic alterations, immuno-
genicity but also on fraction size and total radiation dose. Lee
et al. observed in an animal model that a dose of 15–25 Gy in
one fraction resulted in a dramatical increase in T-cell prim-
ing in draining lymphoid tissues leading to the reduction or
eradication of the primary tumor or distant metastasis in a
CD8+ T cell-dependent fashion and that this phenomenon was
not seen with conventional fractionation.71 CD8+ cells are the
major effector cytotoxic T cells.
Radiation has also effects facilitating the trafficking and
homing of effector T cells to tumors by the induction of
chemokines and endothelial expression of vascular adhe-
sion molecules that facilitate the extravasation of CD8+ T cell
into the tumor. In addition, radiation induces upregulation of
major histocompatibility class I molecules and death recep-
tors improving the recognition of tumor cells by cytotoxic CD8+
T cells. In short, radiation can induce a massive release of can-
cer cell neoantigens to the immune system and can facilitate
the circulation, recognition and killing of tumor cells by effec-
tor T cells. All these immunostimulatory effects of radiation
are faced by immunosuppressive effects of the microenvi-
ronment or produced by radiation itself. The presence in
the tumor microenvironment of cells suppressing antitumor
immunity, such as myeloid-derived suppressor cells or regu-
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nhancement of tumor infiltration by myeloid-derived sup-
ressor cells or killing of radiosensitive effector T cells by
 protracted radiation therapy are examples of immunosup-
ressive effects of radiation.
Ways to enhance immunostimulatory effects of radiation
use of high dose fractions in short overall treatment time)
nd/or to overcome immunosuppressive effects of microen-
ironment (combination of radiation with immunodrugs) are
nder active investigation.
.1.  Radiation  induced  abscopal  effects
here is emerging evidence that radiation therapy not only
cts locally but can also exert distant non-targeted or systemic
ffects.72 Also known as distant bystander or out-of-field
ffects, the term abscopal effect which is derived from the
atin prefix ab- “position away from” and -scopos “mark or
arget for shooting” was proposed to describe a tumor event
ccurring at a distance from the irradiated volume but within
he same organism.73 Clinical reports of an abscopal effect
fter radiation therapy are few, it is observed anectodally and
robably constitutes a clinically under-recognized and under-
eported phenomena. Abscopal effects have been described
fter conventional radiation therapy and more  recently after
blative radiation therapy.74 Two mechanistic explanations
ave been proposed to account for the abscopal effect: the
nduction of cytokines, eliciting augmented tumor surveil-
ance, tumor growth inhibition and tumoricidal effects and/or
he activation of the immune system.75 Evidence in exper-
mental models suggests that the abscopal effect is tumor
pecific and is in part immune mediated and that T cells
re required to mediate distant tumor inhibition induced by
adiation.76
On the other hand, there is an emerging hallmark of can-
er: the ability of tumor cells to evade immune destruction.77
ccording to the theory of immune surveillance that propose
he existence of immunological mechanisms on constant alert
gainst the appearance of transformed cells, the growth of
alignant tumors results from development of evasion mech-
nisms of immune surveillance by neoplastic cells and/or
echanisms of limitation of the attack of the immune sys-
em effector cells.78 Thus, there is a renewed interest in
mmunotherapy not only in finding stimulating factors of
ntitumor immunity but also in the study of tumor immune
vasion mechanisms and pharmacological countermeasures.
For both reasons, there is an emerging interest in combin-
ng radiation therapy and immunotherapy. Recent examples
f objective clinical responses achieved by the combination of
adiotherapy and immunotherapy support the view that both
reatments can act synergistically.79,80 The combination of
adiation therapy and immunotherapy is under active preclin-
cal and clinical investigation. In the USA, more  than 50 clinical
rials are currently testing the addition of radiation therapy to
arious immunotherapies.81,82 Strong efforts should be made
o identify the correct dose, fractionation, target volumes and
equencing with the best immunotherapy agent. As a new
ole for radiation therapy is emerging as a radiation-driven
mmunotherapy, four extremely important final consider-
tions should be made for our Radiation Oncology community.
e  need to refine our knowledge of basic and cancer
1
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immunology to continue basic research in radiobiology labs,
specially in relation to the immune system (immunogenic
cell death). We  need also to enlarge our knowledge of new
immunotherapy drugs (anti CTLA4, anti PD1, . . .)  and to par-
ticipate in clinical research not only recruiting patients but
also designing clinical trials.
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